These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14625878)

  • 41. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series.
    Schwartz TL
    Psychopharmacol Bull; 2002; 36(2):53-7. PubMed ID: 12397840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
    Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
    Schunck T; Erb G; Mathis A; Gilles C; Namer IJ; Hode Y; Demaziere A; Luthringer R; Macher JP
    Neuroimage; 2006 Jul; 31(3):1197-208. PubMed ID: 16600640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D; Torres S; Swain JE; Bradwejn J
    Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
    Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
    Eser D; Schüle C; Baghai T; Floesser A; Krebs-Brown A; Enunwa M; de la Motte S; Engel R; Kucher K; Rupprecht R
    Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
    Dépôt M; Merani S; Bradwejn J; Mukherjee J; Caillé J; Gutkowska J; Caillé G
    J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA.
    Stahl SM
    J Clin Psychiatry; 2004 Mar; 65(3):291-2. PubMed ID: 15096065
    [No Abstract]   [Full Text] [Related]  

  • 49. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trait dissociation affects the behavioral response to cholecystokinin tetrapeptide in healthy man.
    Kellner M; Yassouridis A; Hua Y; Wendrich M; Naber D; Wiedemann K
    Psychiatry Res; 2002 Aug; 111(1):93-6. PubMed ID: 12140124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects.
    Paparrigopoulos T; Tzavellas E; Karaiskos D; Malitas P; Liappas I
    J Psychopharmacol; 2010 Sep; 24(9):1375-80. PubMed ID: 19346278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.
    Gunnarsson T; Mahoney C; Shlik J; Bradwejn J; Knott V
    Pharmacopsychiatry; 2003 Sep; 36(5):181-6. PubMed ID: 14571352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tiagabine improves panic and agoraphobia in panic disorder patients.
    Zwanzger P; Baghai TC; Schüle C; Minov C; Padberg F; Möller HJ; Rupprecht R
    J Clin Psychiatry; 2001 Aug; 62(8):656-7. PubMed ID: 11561942
    [No Abstract]   [Full Text] [Related]  

  • 54. Open-label tiagabine monotherapy for major depressive disorder with anxiety.
    Carpenter LL; Schecter JM; Tyrka AR; Mello AF; Mello MF; Haggarty R; Price LH
    J Clin Psychiatry; 2006 Jan; 67(1):66-71. PubMed ID: 16426090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GABA transporters as drug targets for modulation of GABAergic activity.
    Schousboe A; Sarup A; Larsson OM; White HS
    Biochem Pharmacol; 2004 Oct; 68(8):1557-63. PubMed ID: 15451399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neuropharmacological and genetic study of panic disorder].
    Akiyoshi J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):93-9. PubMed ID: 10495983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
    Otte C; Moritz S; Yassouridis A; Koop M; Madrischewski AM; Wiedemann K; Kellner M
    Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic.
    Ruland T; Domschke K; Schütte V; Zavorotnyy M; Kugel H; Notzon S; Vennewald N; Ohrmann P; Arolt V; Pfleiderer B; Zwanzger P
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1677-82. PubMed ID: 26235955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze.
    Zanoveli JM; Netto CF; Guimarães FS; Zangrossi H
    Peptides; 2004 Nov; 25(11):1935-41. PubMed ID: 15501525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice.
    Dhir A; Kulkarni SK
    Inflammopharmacology; 2006 Dec; 14(5-6):222-5. PubMed ID: 17139446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.